Financial Health Assessment: NORPAK LIMITED

1. Financial Health Score: B-

Explanation: The patient has robust reserves and excellent liquidity, but is exhibiting chronic symptoms of declining vitality. Like an elderly patient with a strong immune system but gradually weakening organ function, NORPAK's balance sheet remains fundamentally sound, yet consecutive years of losses and shrinking activity suggest the business is in a slow managed decline rather than active growth.

2. Key Vital Signs

💓 Liquidity Pulse — Strong

Reading: The patient's circulatory system is functioning well. With nearly £233k in cash and a current ratio of 2.49, there is no immediate risk of financial cardiac arrest. The business can comfortably meet its short-term obligations.

🩺 Balance Sheet Strength — Good

Reading: The skeleton remains sturdy, but bone density is slowly decreasing. Net assets have declined for the third consecutive year. Importantly, there are no long-term liabilities visible, meaning the company carries no structural debt burden — all liabilities are current.

📊 Activity Indicators — Weakening

Reading: These are symptoms of a contracting business. Lower debtors suggest reduced sales activity. Lower stock levels indicate either efficient inventory management or, more concerning, reduced purchasing due to lower demand. The significant decline in fixed assets (25%) with minimal apparent reinvestment suggests the business is consuming rather than renewing its productive capacity.

📈 Profitability — Concerning

Reading: The retained earnings dropped by £9,676, indicating the company made a loss in 2025 (or paid dividends that exceeded profit). This follows a pattern of declining net assets:

The rate of decline has slowed significantly, which could indicate stabilisation, but the patient is still bleeding.

🏦 Capital Structure — Conservative

Reading: The capital structure is overwhelmingly equity-based with no long-term debt. The capital redemption reserve of £42,287 indicates past share buybacks, which is unusual for a company of this size and suggests a deliberate strategy to return capital to shareholders.

3. Diagnosis

Primary Condition: Chronic Managed Decline with Strong Immune Defences

NORPAK LIMITED presents as a long-established business (incorporated 1981) that appears to be in a phase of managed contraction. The principal symptoms are:

1. Consecutive Annual Losses: Net assets have declined from £346,962 (2023) to £275,482 (2025), representing a cumulative erosion of £71,480 over two years — approximately 20.6% of the 2023 value.

2. Shrinking Revenue Indicators: The simultaneous decline in debtors (-12.6%), stocks (-24.1%), and fixed assets (-24.8%) all point to reduced business activity. When a patient's appetite decreases alongside weight loss, it typically indicates an underlying condition requiring investigation.

3. Cash Accumulation Paradox: Despite reporting losses, cash has increased from £189,038 to £233,221. This is possible when a business collects receivables and runs down inventory faster than it pays out — a classic pattern of a business in "harvest mode."

4. Minimal Reinvestment: Tangible fixed assets fell from £51,989 to £39,098, a 25% decline. Without capital reinvestment, the business's productive capacity is gradually atrophying — like muscles wasting from disuse.

5. Historical Context: The dramatic cash fluctuation between 2021 (£84,666) and 2022 (£8,811) then 2023 (£244,858) suggests a significant transaction occurred in that period — possibly a property sale or major asset realisation that temporarily boosted cash reserves.

Secondary Observations:

• Ownership Concentration: Christopher John Parry controls over 75% of shares and voting rights, with significant influence over director appointments. This concentrated control enables swift strategic decisions but concentrates risk.

• Director Role: Alison Mary Parry serves as both director and secretary, which is permitted for small companies but concentrates governance responsibilities.

• No Long-Term Debt: The absence of long-term liabilities is both a strength (no debt servicing burden) and a potential weakness (no leverage to fund growth).

4. Recommendations

🏥 Immediate Actions (0-6 months)

1. Diagnose the Losses: Determine the root cause of declining profitability. Is it revenue erosion, margin compression, or cost inflation? The filed accounts don't include a profit and loss statement, so management should conduct a detailed margin analysis by product line and customer segment.

2. Review Cash Deployment Strategy: With £233,221 sitting in cash (59% of current assets), the business is earning minimal returns. Consider whether this cash should be: - Invested in growth initiatives - Distributed to shareholders as dividends - Placed in interest-bearing deposits

📋 Medium-Term Actions (6-18 months)

3. Strategic Direction Decision: The ownership must decide whether NORPAK is: - A going concern requiring investment for growth - A harvest vehicle maximising cash extraction before eventual wind-down

This decision fundamentally shapes all subsequent financial planning.

4. Asset Reinvestment Assessment: If the business is to continue as a going concern, the declining fixed asset base (£39,098) needs evaluation. Manufacturing businesses typically require ongoing capital investment to remain competitive.

5. Creditor Management: Current liabilities increased by 7.9% to £159,005. While manageable given the liquidity position, this trend should be monitored to ensure supplier relationships remain healthy.

🔮 Long-Term Considerations (18+ months)

6. Succession Planning: With a 43+ year-old company controlled by individuals who may be approaching retirement age, formal succession planning is essential. Options include: - Family succession - Management buyout - Trade sale - Orderly wind-down

7. Working Capital Optimisation: The business holds significant debtors (£128,089). Review credit terms and collection procedures to accelerate cash conversion.

8. Business Model Review: The dual SIC codes (manufacturing and wholesale) suggest a diversified model. Analyse which activities are profitable and which are draining resources.

Summary of Financial Trajectory

``` Net Assets Trend: ▂▂▂▂▂▂▁▁▁ 2014-2021: Recovery 2022-2025: Decline

Cash Position Trend: ▁▁▁▂▁▃▂▃ Historically weak, now strong

Liquidity Health: ████████████████████ Excellent (2.49x)

Profitability Health: ████████░░░░░░░░░░░░ Declining (consecutive losses)

Asset Vitality: ██████████░░░░░░░░░░ Moderate but deteriorating ```